250 related articles for article (PubMed ID: 20094025)
1. Transfusion-related transmission of yellow fever vaccine virus--California, 2009.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2010 Jan; 59(2):34-7. PubMed ID: 20094025
[TBL] [Abstract][Full Text] [Related]
2. Yellow fever vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP).
Staples JE; Gershman M; Fischer M;
MMWR Recomm Rep; 2010 Jul; 59(RR-7):1-27. PubMed ID: 20671663
[TBL] [Abstract][Full Text] [Related]
3. Adverse event reports following yellow fever vaccination.
Lindsey NP; Schroeder BA; Miller ER; Braun MM; Hinckley AF; Marano N; Slade BA; Barnett ED; Brunette GW; Horan K; Staples JE; Kozarsky PE; Hayes EB
Vaccine; 2008 Nov; 26(48):6077-82. PubMed ID: 18809449
[TBL] [Abstract][Full Text] [Related]
4. Review of the risks and benefits of yellow fever vaccination including some new analyses.
Monath TP
Expert Rev Vaccines; 2012 Apr; 11(4):427-48. PubMed ID: 22551029
[TBL] [Abstract][Full Text] [Related]
5. Late vaccination against yellow fever of travelers visiting endemic countries.
Krief I; Goldblatt JG; Paz A; Potasman I
Travel Med Infect Dis; 2006 Mar; 4(2):94-8. PubMed ID: 16887731
[TBL] [Abstract][Full Text] [Related]
6. [Surveillance system for adverse events following immunization against yellow fever in Burkina Faso in 2008. Good practice recommendations].
Yaméogo TM; Breugelmans JG; Kambou JL; Badolo O; Tiendrebéogo S; Traoré E; Avokey F; Yactayo S
Med Trop (Mars); 2009 Aug; 69(4):320-1. PubMed ID: 19725376
[TBL] [Abstract][Full Text] [Related]
7. The effects of yellow fever immunization (17DD) inadvertently used in early pregnancy during a mass campaign in Brazil.
Suzano CE; Amaral E; Sato HK; Papaiordanou PM;
Vaccine; 2006 Feb; 24(9):1421-6. PubMed ID: 16236402
[TBL] [Abstract][Full Text] [Related]
8. Yellow fever vaccination: how much is enough?
Massad E; Coutinho FA; Burattini MN; Lopez LF; Struchiner CJ
Vaccine; 2005 Jun; 23(30):3908-14. PubMed ID: 15917112
[TBL] [Abstract][Full Text] [Related]
9. Prevention of yellow fever in persons traveling to the tropics.
Monath TP; Cetron MS
Clin Infect Dis; 2002 May; 34(10):1369-78. PubMed ID: 11981733
[TBL] [Abstract][Full Text] [Related]
10. Vaccination coverage survey versus administrative data in the assessment of mass yellow fever immunization in internally displaced persons--Liberia, 2004.
Huhn GD; Brown J; Perea W; Berthe A; Otero H; LiBeau G; Maksha N; Sankoh M; Montgomery S; Marfin A; Admassu M
Vaccine; 2006 Feb; 24(6):730-7. PubMed ID: 16182416
[TBL] [Abstract][Full Text] [Related]
11. Yellow fever vaccination coverage among children in Brazilian capitals.
Veras MA; Flannery B; de Moraes JC; da Silva Teixeira AM; Luna EJ;
Vaccine; 2010 Sep; 28(39):6478-82. PubMed ID: 20674878
[TBL] [Abstract][Full Text] [Related]
12. Travel characteristics and yellow fever vaccine usage among US Global TravEpiNet travelers visiting countries with risk of yellow fever virus transmission, 2009-2011.
Jentes ES; Han P; Gershman MD; Rao SR; LaRocque RC; Staples JE; Ryan ET; The Global TravEpiNet Consortium
Am J Trop Med Hyg; 2013 May; 88(5):954-961. PubMed ID: 23458961
[TBL] [Abstract][Full Text] [Related]
13. Yellow fever: epidemiology and prevention.
Barnett ED
Clin Infect Dis; 2007 Mar; 44(6):850-6. PubMed ID: 17304460
[TBL] [Abstract][Full Text] [Related]
14. [Efficacy and safety of vaccination against yellow fever of persons traveling to endemic areas].
Dabrowska MM; Flisiak R
Przegl Epidemiol; 2010; 64(2):319-22. PubMed ID: 20731245
[TBL] [Abstract][Full Text] [Related]
15. [Yellow fever vaccination: update on rare and severe adverse effects].
Receveur MC; Bruyand M; Pistone T; Malvy D
Med Mal Infect; 2009 Apr; 39(4):234-41. PubMed ID: 19167852
[TBL] [Abstract][Full Text] [Related]
16. Pressure-inactivated yellow fever 17DD virus: implications for vaccine development.
Gaspar LP; Mendes YS; Yamamura AM; Almeida LF; Caride E; Gonçalves RB; Silva JL; Oliveira AC; Galler R; Freire MS
J Virol Methods; 2008 Jun; 150(1-2):57-62. PubMed ID: 18420285
[TBL] [Abstract][Full Text] [Related]
17. Randomized, double-blind, phase III, pivotal field trial of the comparative immunogenicity, safety, and tolerability of two yellow fever 17D vaccines (Arilvax and YF-VAX) in healthy infants and children in Peru.
Belmusto-Worn VE; Sanchez JL; McCarthy K; Nichols R; Bautista CT; Magill AJ; Pastor-Cauna G; Echevarria C; Laguna-Torres VA; Samame BK; Baldeon ME; Burans JP; Olson JG; Bedford P; Kitchener S; Monath TP
Am J Trop Med Hyg; 2005 Feb; 72(2):189-97. PubMed ID: 15741556
[TBL] [Abstract][Full Text] [Related]
18. Yellow fever vaccination and increased relapse rate in travelers with multiple sclerosis.
Farez MF; Correale J
Arch Neurol; 2011 Oct; 68(10):1267-71. PubMed ID: 21670384
[TBL] [Abstract][Full Text] [Related]
19. Adverse events associated with 17D-derived yellow fever vaccination--United States, 2001-2002.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2002 Nov; 51(44):989-93. PubMed ID: 12455906
[TBL] [Abstract][Full Text] [Related]
20. Adverse events following yellow fever preventive vaccination campaigns in eight African countries from 2007 to 2010.
Breugelmans JG; Lewis RF; Agbenu E; Veit O; Jackson D; Domingo C; Böthe M; Perea W; Niedrig M; Gessner BD; Yactayo S;
Vaccine; 2013 Apr; 31(14):1819-29. PubMed ID: 23395587
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
